MA52643A - Anticorps se liant spécifiquement au tl1a - Google Patents

Anticorps se liant spécifiquement au tl1a

Info

Publication number
MA52643A
MA52643A MA052643A MA52643A MA52643A MA 52643 A MA52643 A MA 52643A MA 052643 A MA052643 A MA 052643A MA 52643 A MA52643 A MA 52643A MA 52643 A MA52643 A MA 52643A
Authority
MA
Morocco
Prior art keywords
tl1a
binding specifically
antibodies binding
antibodies
specifically
Prior art date
Application number
MA052643A
Other languages
English (en)
Inventor
Adam William Clarke
Bridget Ann Cooksey
Anthony G Doyle
Vanya Pande
Matthew Pollard
Lynn Dorothy Poulton
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of MA52643A publication Critical patent/MA52643A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Sorting Of Articles (AREA)
MA052643A 2015-09-18 2016-09-16 Anticorps se liant spécifiquement au tl1a MA52643A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562220442P 2015-09-18 2015-09-18

Publications (1)

Publication Number Publication Date
MA52643A true MA52643A (fr) 2021-03-24

Family

ID=57043002

Family Applications (2)

Application Number Title Priority Date Filing Date
MA42825A MA42825B1 (fr) 2015-09-18 2016-09-16 Anticorps se liant spécifiquement à tl1a
MA052643A MA52643A (fr) 2015-09-18 2016-09-16 Anticorps se liant spécifiquement au tl1a

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA42825A MA42825B1 (fr) 2015-09-18 2016-09-16 Anticorps se liant spécifiquement à tl1a

Country Status (33)

Country Link
US (4) US10138296B2 (fr)
EP (2) EP3693393A1 (fr)
JP (2) JP7013366B2 (fr)
KR (1) KR101998535B1 (fr)
CN (1) CN108137693B (fr)
AR (1) AR106055A1 (fr)
AU (2) AU2016323460B2 (fr)
BR (1) BR122021002400A8 (fr)
CA (2) CA3306751A1 (fr)
CL (1) CL2018000711A1 (fr)
CO (1) CO2018003736A2 (fr)
CY (1) CY1123499T1 (fr)
DK (1) DK3350223T3 (fr)
EA (1) EA201890756A1 (fr)
ES (1) ES2810751T3 (fr)
HR (1) HRP20201323T1 (fr)
HU (1) HUE051496T2 (fr)
IL (1) IL257761B2 (fr)
LT (1) LT3350223T (fr)
MA (2) MA42825B1 (fr)
MD (1) MD3350223T2 (fr)
MX (1) MX2018003185A (fr)
PE (1) PE20181080A1 (fr)
PH (1) PH12018500580B1 (fr)
PL (1) PL3350223T3 (fr)
PT (1) PT3350223T (fr)
RS (1) RS60703B1 (fr)
SI (1) SI3350223T1 (fr)
SM (1) SMT202000500T1 (fr)
TW (1) TWI703158B (fr)
UA (1) UA125284C2 (fr)
WO (1) WO2017049024A1 (fr)
ZA (1) ZA201801427B (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110229471A1 (en) 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
EP3495389A1 (fr) 2011-09-30 2019-06-12 Teva Pharmaceuticals Australia Pty Ltd Anticorps dirigés contre l'tl1a et leurs utilisations
KR20240122922A (ko) 2013-03-27 2024-08-13 세다르스-신나이 메디칼 센터 Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한 섬유증 및 염증의 완화 및 반전
EP3022295A4 (fr) 2013-07-19 2017-03-01 Cedars-Sinai Medical Center Signature de la voie de signalisation de tl1a (tnfsf15)
TWI703158B (zh) 2015-09-18 2020-09-01 美商希佛隆公司 特異性結合tl1a之抗體
JP7240789B2 (ja) * 2015-12-04 2023-03-16 ユニバーシティー オブ アイオワ リサーチ ファンデーション 脳症／せん妄のスクリーニングおよびモニタリングのためのシステム
CR20180365A (es) 2015-12-16 2018-09-28 Amgen Inc PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
CN109462996A (zh) 2016-03-17 2019-03-12 西达-赛奈医疗中心 通过rnaset2诊断炎性肠病的方法
MY191324A (en) 2016-10-26 2022-06-15 Cedars Sinai Medical Center Neutralizing anti-tl1a monoclonal antibodies
CA3061467A1 (fr) * 2017-04-28 2019-10-24 Ajinomoto Co., Inc. Compose renfermant une substance ayant une affinite pour une proteine soluble, fraction clivable, et groupe reactif, ou sel de celui-ci
CN119735681A (zh) 2018-04-25 2025-04-01 普罗米修斯生物科学公司 优化的抗tl1a抗体
EP3969621A4 (fr) 2019-05-14 2023-01-25 Prometheus Biosciences, Inc. Méthodes, systèmes et dispositifs de sélection de patient tl1a
TW202600603A (zh) 2019-10-24 2026-01-01 美商普羅米修斯生物科學股份有限公司 針對類-tnf配體1a (tl1a)之人類化抗體及其用途
CA3190012A1 (fr) * 2020-08-19 2022-02-24 Adam ZWOLAK Materiaux et procedes d'utilisation de ligands modifies
KR20230158494A (ko) * 2021-02-18 2023-11-20 프로메테우스 바이오사이언시즈, 인크. 항-tl1a 항체 조성물 및 폐에서의 치료 방법
CN117202932A (zh) * 2021-02-18 2023-12-08 普罗米修斯生物科学公司 治疗肺部的抗tl1a抗体组合物和方法
AR130041A1 (es) 2022-07-27 2024-10-30 Cephalon Llc Formulaciones de anticuerpos anti-tl1a
CN119894931A (zh) 2022-07-27 2025-04-25 赛福伦有限责任公司 用于治疗溃疡性结肠炎和克罗恩病的抗tl1a抗体
AU2024273758A1 (en) 2023-05-17 2025-12-04 Genentech, Inc. Anti-tl1a antibody therapeutic methods
WO2024263868A2 (fr) * 2023-06-21 2024-12-26 Paragon Therapeutics, Inc. Compositions d'anticorps tl1a et procédés d'utilisation
TW202515910A (zh) * 2023-06-22 2025-04-16 美商派拉岡醫療公司 Il-17抗體組合物及使用方法
JP2026522632A (ja) * 2023-06-22 2026-07-08 パラゴン セラピューティクス、インコーポレイテッド Ｉｌ－２３抗体組成物および使用法
IL325993A (en) 2023-08-11 2026-03-01 Paragon Therapeutics Inc TL1A binding proteins and methods of use
US12473370B2 (en) 2023-10-03 2025-11-18 Absci Corporation TL1A associated antibody compositions and methods of use
CN121851173A (zh) * 2023-11-30 2026-04-14 北京智仁美博生物科技有限公司 抗肿瘤坏死因子样配体1a的抗体及其用途
AU2024406222A1 (en) 2023-12-20 2026-06-04 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rβ) and related methods
CN120424214A (zh) * 2024-02-05 2025-08-05 三生国健药业（上海）股份有限公司 一种抗tl1a抗体及其制备方法和用途
AU2025218720A1 (en) 2024-02-06 2026-05-21 Paragon Therapeutics, Inc. Il-23 antibody compositions and methods of use
WO2025171006A1 (fr) 2024-02-06 2025-08-14 Paragon Therapeutics, Inc. Compositions de protéines de liaison à il-23 et procédés d'utilisation
CN120590530A (zh) * 2024-03-05 2025-09-05 帆礼生物技术(武汉)有限公司 靶向tl1a的抗体及其应用
TW202613167A (zh) 2024-05-17 2026-04-01 美商建南德克公司 使用抗ｔｌ１ａ抗體治療發炎性腸病之方法
WO2026072993A1 (fr) 2024-09-27 2026-04-02 Genentech, Inc. Méthodes de traitement de la stéatohépatite associée à un dysfonctionnement métabolique avec un anticorps anti-tl1a
WO2026072983A1 (fr) 2024-09-27 2026-04-02 Genentech, Inc. Méthodes de traitement de la dermatite atopique avec un anticorps anti-tl1a
WO2026080698A1 (fr) * 2024-10-11 2026-04-16 Spyre Therapeutics, Inc. MÉTHODES DE TRAITEMENT DE MALADIES INFLAMMATOIRES GASTRO-INTESTINALES UTILISANT UN ANTICORPS SE LIANT À α4β7 ET UN ANTICORPS SE LIANT À TL1A
CN119552252B (zh) * 2025-01-16 2025-11-25 华润生物医药有限公司 抗tl1a抗体及其制备方法和应用
WO2026158530A1 (fr) * 2025-01-24 2026-07-30 信立泰(成都)生物技术有限公司 Anticorps anti-tl1a ou son fragment de liaison à l'antigène, et utilisation
WO2026165337A1 (fr) 2025-01-31 2026-08-06 Genentech, Inc. Méthodes de traitement d'une maladie intestinale inflammatoire pédiatrique avec un anticorps anti-tl1a

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7597886B2 (en) 1994-11-07 2009-10-06 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US7820798B2 (en) 1994-11-07 2010-10-26 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
US6548062B2 (en) * 2000-02-29 2003-04-15 Cephalon, Inc. Method of treating cancer with anti-neurotrophin agents
EP1355919B1 (fr) 2000-12-12 2010-11-24 MedImmune, LLC Molecules a demi-vies longues, compositions et utilisations de celles-ci
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
AU2003293543A1 (en) 2002-12-13 2004-07-09 Abgenix, Inc. System and method for stabilizing antibodies with histidine
DK1667730T3 (da) 2003-08-20 2013-09-23 Univ Miami Sammensætninger og fremgangsmåder til behandling af inflammatorisk lungesygdom
BRPI0509201A (pt) 2004-03-23 2007-08-28 Biogen Idec Inc agentes de acoplamento de receptor e usos terapêuticos destes
GB0521621D0 (en) * 2005-10-24 2005-11-30 Domantis Ltd Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
US20090317388A1 (en) 2005-05-25 2009-12-24 Linda Burkly Tl1a in treatment of disease
DK1919954T3 (en) 2005-08-30 2017-01-30 Univ Miami Immune modulating tumor necrosis factor receptor (TNFR25) - agonists, antagonists and immunotoxins
US20090269345A1 (en) 2005-12-23 2009-10-29 Rong Fan CLN248 Antibody Compositions and Methods of Use
US20110217310A1 (en) 2007-01-10 2011-09-08 Siegel Richard M Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology
US20100190162A1 (en) * 2007-02-26 2010-07-29 Cedars-Sinai Medical Center Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease
WO2009052512A2 (fr) 2007-10-19 2009-04-23 Cedars-Sinai Medical Center Procédés d'utilisation de variants génétiques pour diagnostiquer et prévenir la maladie inflammatoire de l'intestin
MX2010005282A (es) 2007-11-13 2010-08-31 Teva Pharma Anticuerpos humanizados contra tl1a.
WO2010118210A1 (fr) 2009-04-08 2010-10-14 Cedars-Sinai Medical Center Méthodes de prévision d'une complication et d'une chirurgie dans la maladie de crohn
EP2519260A2 (fr) 2009-12-31 2012-11-07 Deutsches Krebsforschungszentrum Nouveaux modulateurs de signalisation par trail
JO3375B1 (ar) * 2010-11-08 2019-03-13 Regeneron Pharma أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a)
AU2012259312A1 (en) 2011-05-20 2013-12-12 Government Of The United States, As Represented By The Secretary Department Of Health And Human Services Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology and antibodies thereof
US20140170157A1 (en) 2011-06-15 2014-06-19 Glaxosmithkline Intellectual Property (No.2) Limited Method of selecting therapeutic indications
EP3495389A1 (fr) * 2011-09-30 2019-06-12 Teva Pharmaceuticals Australia Pty Ltd Anticorps dirigés contre l'tl1a et leurs utilisations
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
WO2014106602A1 (fr) 2013-01-02 2014-07-10 Glenmark Pharmaceuticals S.A. Anticorps qui se lient à tl1a et leurs utilisations
KR20240122922A (ko) 2013-03-27 2024-08-13 세다르스-신나이 메디칼 센터 Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한 섬유증 및 염증의 완화 및 반전
EP2981286A4 (fr) * 2013-04-05 2016-08-24 Hoffmann La Roche Anticorps anti-il-4 et anticorps bispécifiques et leurs utilisations
KR20210107176A (ko) 2013-05-17 2021-08-31 세다르스-신나이 메디칼 센터 크론병과 연관된 tnfsf15와 dcr3의 변이체
EP2996717A4 (fr) 2013-05-17 2016-11-23 Cedars Sinai Medical Center Effets distincts d'ifn gamma et d'il-17 sur une inflammation et une fibrose modulées par tl1a
EP3022295A4 (fr) 2013-07-19 2017-03-01 Cedars-Sinai Medical Center Signature de la voie de signalisation de tl1a (tnfsf15)
CA2922381A1 (fr) 2013-09-06 2015-03-12 Cedars-Sinai Medical Center Systemes, dispositifs et procedes pour therapie anti-tl1a
CN105814081B (zh) * 2013-11-13 2021-02-02 辉瑞大药厂 肿瘤坏死因子样配体1a特异性抗体及其组合物和用途
DK3283499T5 (da) 2015-04-15 2024-09-16 Biosearch Tech Inc Dual quencher probes
WO2016186972A1 (fr) 2015-05-15 2016-11-24 Cedars-Sinai Medical Center Modèles, méthodes et compositions pour traiter une infection intestinale inflammatoire
HK1257443A1 (zh) 2015-08-21 2019-10-18 The Children's Hospital Of Philadelphia 治疗具有dcr3或dcr3网络基因中的遗传变异的患者的自身免疫病症的方法
TWI703158B (zh) 2015-09-18 2020-09-01 美商希佛隆公司 特異性結合tl1a之抗體
US20180319889A1 (en) 2015-11-02 2018-11-08 La Jolla Institute For Allergy & Immunology Method and medicament for treating airway and/or lung diseases
CR20180365A (es) 2015-12-16 2018-09-28 Amgen Inc PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
CN109462996A (zh) 2016-03-17 2019-03-12 西达-赛奈医疗中心 通过rnaset2诊断炎性肠病的方法
US10968279B2 (en) 2016-05-09 2021-04-06 Bristol-Myers Squibb Company TL1A antibodies and uses thereof
GB201608323D0 (en) 2016-05-12 2016-06-29 Ucb Biopharma Sprl Pharmaceutical compositions
RU2746314C2 (ru) 2016-06-09 2021-04-12 Пеликан Терапьютикс, Инк. Антитела анти-tnfrsf25
MY191324A (en) 2016-10-26 2022-06-15 Cedars Sinai Medical Center Neutralizing anti-tl1a monoclonal antibodies
US10626180B2 (en) 2017-04-20 2020-04-21 Cedars-Sinai Medical Center Methods of treating and predicting non-response to anti-TNF treatment in subjects with inflammatory bowel disease
CN119735681A (zh) 2018-04-25 2025-04-01 普罗米修斯生物科学公司 优化的抗tl1a抗体
PT3774897T (pt) 2018-04-30 2023-11-10 Cedars Sinai Medical Center Métodos e sistemas para seleção e tratamento de pacientes com doenças inflamatórias
CA3121167A1 (fr) 2018-11-29 2020-06-04 Cedars-Sinai Medical Center Procedes de classification et de traitement d'une sous-population de patients atteints d'une maladie intestinale inflammatoire
EP3969621A4 (fr) 2019-05-14 2023-01-25 Prometheus Biosciences, Inc. Méthodes, systèmes et dispositifs de sélection de patient tl1a
TW202600603A (zh) 2019-10-24 2026-01-01 美商普羅米修斯生物科學股份有限公司 針對類-tnf配體1a (tl1a)之人類化抗體及其用途
CA3162905A1 (fr) 2019-11-27 2021-06-03 Cedars-Sinai Medical Center Prediction de manifestations extra-intestinales de maladies intestinales inflammatoires
EP4162076A4 (fr) 2020-06-03 2024-10-02 Cedars-Sinai Medical Center Traitements pour une sous-population de patients atteints d'une maladie intestinale inflammatoire
EP4162067A4 (fr) 2020-06-03 2024-07-10 Cedars-Sinai Medical Center Méthodes et systèmes de mesure de la récurrence d'une maladie après opération
EP4171632A2 (fr) 2020-06-26 2023-05-03 Pfizer Inc. Méthodes de traitement d'une affection abdominale inflammatoire à l'aide d'anticorps tl1a
IL302791A (en) 2020-11-13 2023-07-01 Prometheus Biosciences Inc Methods, systems, and kits for treatment of inflammatory diseases targeting tl1a
WO2022119842A1 (fr) 2020-12-01 2022-06-09 Cedars-Sinai Medical Center Procédés et systèmes pour stratification de patients atteints de maladie inflammatoire
EP4263585A4 (fr) 2020-12-21 2024-11-27 Cedars-Sinai Medical Center Compositions thérapeutiques de tl1a et méthodes de traitement les utilisant
KR20230158494A (ko) 2021-02-18 2023-11-20 프로메테우스 바이오사이언시즈, 인크. 항-tl1a 항체 조성물 및 폐에서의 치료 방법
GEAP202416596A (en) 2021-02-18 2024-10-28 Cedars Sinai Medical Center Compositions comprising humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof
EP4330434A1 (fr) 2021-04-28 2024-03-06 Cedars-Sinai Medical Center Procédés et kits de sélection des patients pour thérapies ciblant tl1a
WO2023102051A1 (fr) 2021-12-01 2023-06-08 Cedars-Sinai Medical Center Phagocytes mononucléaires intestinaux en tant que biomarqueur de pronostic pour la maladie de crohn
US20260000713A1 (en) 2021-12-01 2026-01-01 Cedars-Sinai Medical Center Microbial metabolites on intestinal inflammation
AR128226A1 (es) 2022-01-07 2024-04-10 Prometheus Biosciences Inc Métodos para tratar enfermedades inflamatorias con una combinación de inhibidores de tl1a e inhibidores de il23
US20240059799A1 (en) 2022-05-11 2024-02-22 Pfizer Inc. Anti-tl1a antibodies and methods of use thereof

Also Published As

Publication number Publication date
JP7341259B2 (ja) 2023-09-08
TW201722990A (zh) 2017-07-01
BR112018005407A8 (pt) 2023-01-24
CN108137693A (zh) 2018-06-08
US11220549B2 (en) 2022-01-11
EP3350223B1 (fr) 2020-06-17
BR112018005407A2 (en) 2018-10-09
MA42825B1 (fr) 2020-09-30
CL2018000711A1 (es) 2018-11-23
EA201890756A1 (ru) 2018-08-31
CA3306751A1 (en) 2026-05-13
MD3350223T2 (ro) 2020-09-30
AR106055A1 (es) 2017-12-06
LT3350223T (lt) 2020-10-26
WO2017049024A1 (fr) 2017-03-23
MX2018003185A (es) 2018-08-01
PH12018500580B1 (en) 2023-01-11
BR122021002400A2 (fr) 2018-10-09
ZA201801427B (en) 2019-06-26
US20250179202A1 (en) 2025-06-05
US20170081400A1 (en) 2017-03-23
PH12018500580A1 (en) 2018-10-15
SI3350223T1 (sl) 2020-10-30
DK3350223T3 (da) 2020-08-24
US12162946B2 (en) 2024-12-10
CO2018003736A2 (es) 2018-07-10
JP7013366B2 (ja) 2022-02-15
HUE051496T2 (hu) 2021-03-01
AU2016323460A1 (en) 2018-03-29
PT3350223T (pt) 2020-08-05
IL257761A (en) 2018-04-30
AU2023203440A1 (en) 2023-06-29
US20190106486A1 (en) 2019-04-11
EP3350223A1 (fr) 2018-07-25
CN108137693B (zh) 2021-11-26
SMT202000500T1 (it) 2020-11-10
PL3350223T3 (pl) 2021-03-08
US20220185902A1 (en) 2022-06-16
US10138296B2 (en) 2018-11-27
HRP20201323T1 (hr) 2020-11-27
AU2023203440B2 (en) 2026-04-16
TWI703158B (zh) 2020-09-01
IL257761B (en) 2022-11-01
HK1256300A1 (zh) 2019-09-20
RS60703B1 (sr) 2020-09-30
KR20180048712A (ko) 2018-05-10
IL257761B2 (en) 2023-03-01
EP3693393A1 (fr) 2020-08-12
JP2022051771A (ja) 2022-04-01
PE20181080A1 (es) 2018-07-05
UA125284C2 (uk) 2022-02-16
CA2997015A1 (fr) 2017-03-23
HK1251002A1 (en) 2019-01-18
NZ740731A (en) 2024-07-26
BR122021002400A8 (pt) 2023-01-24
KR101998535B1 (ko) 2019-07-09
JP2018528773A (ja) 2018-10-04
ES2810751T3 (es) 2021-03-09
CY1123499T1 (el) 2022-03-24
AU2016323460B2 (en) 2023-06-15

Similar Documents

Publication Publication Date Title
HUE051496T2 (hu) TL1A-hoz specifikusan kötõdõ ellenanyagok
MA51734A (fr) Anticorps se liant à gprc5d
KR102355950B9 (ko) Tigit에 대한 항체
IL258909A (en) Antibodies specifically binding pd-1 and their uses
IL259173A (en) Ctla4 binders
MA46354A (fr) Molécules se liant spécifiquement au vph
EP3461261A4 (fr) Protéines se liant au fragment monocaténaire variable de cd3
MA42380A (fr) Anticorps se liant à tau
MA45004A (fr) Anticorps spécifiques anti-wt1-hla
EP3334757A4 (fr) Anticorps anti-tigit
EP3297671A4 (fr) Anticorps anti-ror1
DK3242892T3 (da) Modificerede april-bindende antistoffer
MA42377A (fr) Anticorps se liant à tau
PL3177644T3 (pl) Immunologiczne reagenty wiążące do PD-1
HUE048667T2 (hu) AXL-hez kötõdõ ellenanyagok
DK3221363T3 (da) Antistoffer mod cd73 og anvendelser deraf
MA49034A (fr) Anticorps anti-lag3
DK2970464T3 (da) Anti-lag-3-bindende proteiner
MA49289A (fr) Anticorps se liant à steap-1
IL263272A (en) Anti-coagulation factor xi antibodies
HUE051357T2 (hu) IL-23 kötõ antitestek
EP3375873A4 (fr) Polypeptide se liant aux immunoblobulines
MA51554A (fr) Anticorps il-6 améliorés
EP2949750A4 (fr) Peptide liant les anticorps
EP3349794A4 (fr) Anticorps anti-cd115